Risk of Herpes Zoster in patients receiving anti-TNF-α in the prospective French RATIO registry

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 1, 2012, Pages 726-729

  Serac, Gaelle ^a   Tubach, Florence ^a   Mariette, Xavier ^b   Salmon Céron, Dominique ^a   Ravaud, Philippe ^a   Lioté, Frederic ^a   Laharie, David ^c   Ziza, Jean Marc ^d   Marguerie, Laurent ^e   Bonnet, Christine ^f   Falgarone, Geraldine ^g   Nicolas, Nathalie ^a   Lortholary, Olivier ^a   Chosidow, Olivier ^h  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^e Institut Calot Helio Marin   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; VALACICLOVIR;

ADULT; AGED; CLINICAL ARTICLE; DISEASE REGISTRY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; HERPES ZOSTER; HUMAN; INFECTION RISK; LETTER; MALE; MENINGITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

EID: 84857041012     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.383     Document Type: Letter

References (14)

1. Askling J, Fored CM, Brandt L et al. (2007) Timedependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66:1339-44 (Pubitemid 47492478)
2. Dixon WG, Symmons DPM, Lunt M et al. (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 56:2896-904 (Pubitemid 47502735)
3. Flynn JL, Goldstein MM, Chan J et al. (1995)
4. Furst DE, Schiff MH, Fleischmann RM et al. (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563-71 (Pubitemid 37549331)
5. Garciá-Doval I, Pérez-Zafrilla B, Descalzo MA et al. (2010) Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 69:1751-5
6. Gourishankar S, McDermid JC, Jhangri GS et al. (2004) Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4:108-15 (Pubitemid 38155496)
7. Keystone EC, Kavanaugh AF, Sharp JT et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400-11 (Pubitemid 38608061)
8. Moore RD, Chaisson RE (1996) Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 124: 633-42 (Pubitemid 26103837)
9. Salmon-Ceron D, Tubach F, Lortholary O et al. (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616-23
10. Steer CB, Szer J, Sasadeusz J et al. (2000) Varicellazoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 25:657-64 (Pubitemid 30156592)
11. Strangfeld A, Listing J, Herzer P et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-44
12. Tubach F, Salmon D, Ravaud P et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60: 1884-94
13. Tubach F, Salmon-Céron D, Ravaud P et al. (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 72:456-60 (Pubitemid 41821398)
14. Wallis RS (2008) Tumour necrosis factor antagonists: Structure, function, and tuberculosis risks. Lancet Infect Dis 8:601-11